

Metabonomic Applications in Drug Discovery

Michael D. Reily

Pfizer Global R&D, Ann Arbor Laboratories, Ann Arbor, MI

The emerging application of metabonomics has been shown to be useful for a variety of pharmaceutical applications including the development of a rapid in vivo toxicity screen, elucidation of mechanisms of toxicity, disease or drug action, and identification of biofluid-born biomarkers. This presentation will briefly discuss the background of metabonomics, the rationale for its utility in pharmaceutical research and the outlook for its future. Several examples will be presented where metabonomics has been a useful adjunct to traditional studies for both toxicity and efficacy.